Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy and dosing convenience across respiratory, dermatology, and gastroenterology indications Interim safety and pharmacokinetic data from BBT002-01 study anticipated in Q1 2026 The clearance of...
Read More Details
Finally We wish PressBee provided you with enough information of ( Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001 )
Also on site :
- Exactly How Many Times a Week To Walk To Improve Your Heart Health, According to Cardiologists
- Los Angeles unrest: Is Trump allowed to deploy National Guard troops?
- DWTS Pros Support Beloved Mirrorball Winner, 38, Amid Personal News